Skip to main content

Table 2 Outcome measures

From: Study design to evaluate a group-based therapy for support persons of adults on buprenorphine/naloxone

Source

Timepoint

Outcome

Description

Primary outcome measures

 EMR

6, 12

Buprenorphine retention

Percentage of patients who initiated buprenorphine who have at least 6 and 12 months of continuous treatment with buprenorphine with no more than a 7-day lapse between prescriptions [51, 52]

Number of days of longest continuous buprenorphine treatment with no breaks in care

Source

 

Outcome

Description

Secondary patient outcome measures

 P INT

SP INT

BL, 3, 12

BL, 3, 12

Patient opioid use

Heroin, prescription opioid, and other opioid use in the past 30 days using questions from the National Survey on Drug Use and Health [57,58,59]

 EMR

6, 12

Medication adherence

Percentage of patients with a buprenorphine prescription with a urine test positive for buprenorphine metabolites

 EMR

6, 12

OUD treatment retention

Percentage of patients who initiated OBOT who had continued visits (no more than a 30-day lapse between visits) with any provider for a substance use disorder for 3, 6, and 12 months [8, 56]

 P INT

 SP INT

BL, 3, 12

BL, 3, 12

Patient other substance use

Alcohol and other drug use in the past 30 days [58, 59]

 P INT

BL, 3, 12

Overdose risk

Opioid Overdose Risk Assessment scale [60]

 P INT

BL, 3, 12

Patient Substance use problems

Substance-related problems in the past 30 days using the Short Inventory of Problems

 P INT

BL, 3, 12

Patient health

Physical health in the past 30 days; depression and anxiety

 P INT

BL, 3, 12

Quality of life

Functional impairment in work/school, family, and social life using the 5-item Sheehan Disability Scale [61]

 P INT

BL, 3, 12

Communication

Adapted from the FACES IV [62]

 P INT

BL, 3, 12

Employment status

Full-time, part-time, unemployed, other (e.g., students, persons keeping house or caring for children full time, retired or disabled persons) [63]

 EMR

 P INT

6, 12

BL, 3, 12

Healthcare utilization

Number of outpatient medical and behavioral health visits over the 12-month period

 P INT

3, 12

Treatment satisfaction

Client Satisfaction Questionnaire (CSQ-8) [64]

Secondary SP outcome measures

 SP INT

BL, 3, 12

Health

Physical health in the past 30 days; depression and anxiety

 SP INT

BL, 3, 12

Substance use

Alcohol and other drug use in the past 30 days [58, 59]

 SP INT

BL, 3, 12

Quality of life

Functional impairment in work/school, family, and social life using the 5-item Sheehan Disability Scale [61]

 SP INT

BL, 3, 12

Communication

Adapted from the FACES IV [62]

 SP INT

3

INSPIRE satisfaction

Client Satisfaction Questionnaire (CSQ-8) adapted to INSPIRE [64]

  1. BL: baseline; 3: 3-month follow-up; 6: 6-month; 12: 12-month follow-up; EMR: electronic medical record; P INT: patient interview; SP INT: support person interview; FACES IV: Family Adaptability and Cohesion Scale IV; OBOT: office-based opioid treatment